"CMT management held a Type C meeting with the Food and Drug Administration (FDA) on 16 January 2024.
FDA provided its written responses regarding potency assay development and comparability studies for
Elate Ocular® drug given the pathogen inactivation steps to be implemented in the drug manufacturing
process. CMT management is assessing the FDA’s written responses and reviewing the Elate Ocular®
development plan. Regeneus believes it to be unlikely that Phase 3 studies can be initiated in 2024, as
originally disclosed in the Shareholder Update Presentation on 28 September 2023."
(emphasis mine)
I was wondering why a phase 3 trial company would be so cheap.
The 100:1 consolidation will push the SP to 70c and give them more leg room for a discounted CR to pay for the trial.
Still looks interesting but probably need to wait til Q4 2024 to see how things look.
- Forums
- ASX - By Stock
- CMB
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CMB (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.772M |
Open | High | Low | Value | Volume |
40.5¢ | 40.5¢ | 40.0¢ | $136 | 341 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 266 | 40.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 1910 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 266 | 0.405 |
2 | 5692 | 0.400 |
1 | 2000 | 0.350 |
1 | 2500 | 0.200 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 1910 | 1 |
0.500 | 51 | 1 |
0.545 | 13403 | 1 |
0.600 | 2000 | 1 |
0.000 | 0 | 0 |
Last trade - 15.26pm 05/08/2024 (20 minute delay) ? |
Featured News
CMB (ASX) Chart |